[Effects of neoadjuvant chemoradiotherapy on the rates of sphincter preserving surgery in lower rectal cancer and analysis of their prognostic factors]
- PMID: 27938574
- DOI: 10.3760/cma.j.issn.0529-5815.2016.06.005
[Effects of neoadjuvant chemoradiotherapy on the rates of sphincter preserving surgery in lower rectal cancer and analysis of their prognostic factors]
Abstract
Objectives: To identify independent factors of sphincter preserving surgery, and to evaluated whether preoperative chemoradiotherapy (CRT) improves the sphincter preservation rate for lower rectal cancers. Methods: A total of 541 consecutive patients who underwent curative surgery for locally advanced rectal cancer (cT3-4Nx or cTxN+ ) within 6 cm of the anal verge with or without neoadjuvant CRT in Department of Colorectal Surgery, Union Hospital, Fujian Medical University between September 2000 and September 2013 were reviewed. Of these, 333 patients underwent surgery alone (Non-CRT group) and 208 patients also received preoperative chemoradiotherapy (CRT group). Clinical data were retrospectively reviewed to determine the factors influencing sphincter preservation, and to evaluate sphincter preservation rate according to tumor height over 1-cm intervals. The categorical variables were compared using χ2 test and Fisher exact test. Continuous variables were compared using t test. Logistic regression was used to identify factors influencing sphincter preservation. A receiver operating characteristic (ROC) curve was constructed, and Youden's index was calculated to evaluate the predictive abilities of factors. Results: Multivariate analysis indicated that the independent factors influencing sphincter preservation were tumor height (OR=5.867, 95% CI: 4.155 to 8.285, P=0.000), pathological T stage (OR=0.688, 95% CI: 0.462 to 1.025, P=0.066), CRT (OR=2.088, 95% CI: 0.971 to 4.492, P=0.060) and histopathological type (OR=0.288, 95% CI: 0.136 to 0.611, P=0.001). The results of ROC analysis showed that the cut-off points for factors affecting sphincter preservation were as follows: (1) tumor height prior to CRT higher than 4.5 cm, (2) not mucinous or signet ring adenocarcinoma, (3) pathological T stage higher than T3, (4) had received preoperative CRT. In an analysis according to tumor height, the sphincter preservation rate was higher in CRT group only when tumor was located in 3.0 to 3.9 cm and 4.0 to 4.9 cm from the annal verge (3.0 to 3.9 cm, 59.4% vs. 2.8%, χ2=26.138, P=0.000; 4.0 to 4.9 cm, 76.9% vs. 37.9%, χ2=10.563, P=0.001). Conclusions: There is a large increased rate of sphincter preservation when patients meet the following conditions: (1) tumor height prior to CRT higher than 4.5 cm, (2) not mucinous or signet ring adenocarcinoma, (3)pathological T stage higher than T3, (4) had received preoperative CRT. Only when tumors are between 3 and 5 cm from the anal verge, CRT could increase the rate of anal sphincter preservation.
Similar articles
-
Pre-operative chemo-radiotherapy improves the sphincter preservation rate in patients with rectal cancer located within 3 cm of the anal verge.Eur J Surg Oncol. 2006 Mar;32(2):162-7. doi: 10.1016/j.ejso.2005.10.002. Epub 2005 Nov 11. Eur J Surg Oncol. 2006. PMID: 16289718
-
[Effects of tumor distance from anal verge and types of operations on survival outcomes for low rectal cancer after neoadjuvant chemoradiotherapy].Zhonghua Yi Xue Za Zhi. 2014 Jun 10;94(22):1705-9. Zhonghua Yi Xue Za Zhi. 2014. PMID: 25151899 Chinese.
-
Clinicopathological analysis of distal margin for rectal cancer after preoperative chemoradiation therapy.Hepatogastroenterology. 2012 Oct;59(119):2142-6. doi: 10.5754/hge11840. Hepatogastroenterology. 2012. PMID: 22366527
-
Sphincter preservation therapy for rectal cancer.Clin Adv Hematol Oncol. 2003 Dec;1(12):735-40. Clin Adv Hematol Oncol. 2003. PMID: 16258478 Review.
-
Total Neoadjuvant Therapy vs Standard Therapy in Locally Advanced Rectal Cancer: A Systematic Review and Meta-analysis.JAMA Netw Open. 2020 Dec 1;3(12):e2030097. doi: 10.1001/jamanetworkopen.2020.30097. JAMA Netw Open. 2020. PMID: 33326026 Free PMC article.
Cited by
-
Recombinant human endostatin combined with radiotherapy inhibits colorectal cancer growth.BMC Cancer. 2017 Dec 28;17(1):899. doi: 10.1186/s12885-017-3903-3. BMC Cancer. 2017. PMID: 29282026 Free PMC article.
-
Predictive model for sphincter preservation in lower rectal cancer.World J Clin Oncol. 2025 Aug 24;16(8):107596. doi: 10.5306/wjco.v16.i8.107596. World J Clin Oncol. 2025. PMID: 40901315 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
Research Materials